Einsele_edit_final.qxp 11/8/09 10:31 am Page 44
Infection in Haematology
tool both to control CMV infection and to minimise the adverse
effects caused by antiviral drugs (ganciclovir: myelosuppression; Götz Ulrich Grigoleit is a senior physician in the Stem Cell Transplant Unit at the
foscarnet: renal toxicity) or drug resistance. Immunotherapeutic
Julius Maximilians University in Würzburg. His scientific work is mainly focused on
the specific immune response to cytomegalovirus (CMV) and self-antigens after
approaches include the transfer of CMV-specific cytotoxic T-
allogeneic haematopoietic stem cell transplantation (alloHSCT). He has conducted
lymphocytes
37,38
or a vaccination with antigen-pulsed professional immunotherapeutic clinical trials to control CMV infection after alloHSCT by dendritic
antigen-presenting cells.
39
Novel antiviral agents without
cells and specific T-cell transfer. His main experience is in T-cell immunology and
modelling of immune responses post-alloHSCT to mediate disease control.
myelosuppression or renal toxicity (e.g. maribavir)
40
may, if the
ongoing studies confirm safety and efficacy for CMV prophylaxis, Markus Kapp is a resident physician in the Stem Cell Transplant Unit at Julius
offer new possibilities in the prophylactic treatment of CMV
Maximilians University in Würzburg. His main focus is on the establishment of
infection in the immunocompromised host.
methods to monitor tumour-associated-antigen (TAA)-specific T-cell responses.
Furthermore, he has evaluated the impact of CD8
+
T-cell responses directed to TAAs
in disease control after allogeneic haematopoietic stem cell transplantation (alloHSCT).
CMV infection leads to a variety of direct and indirect effects. Due
Dr Kapp’s main experience is in T-cell immunology, especially the monitoring and
to the limited number of agents with anti-CMV efficacy, both
modelling of immune responses post-alloHSCT to mediate disease control.
prophylactic and pre-emptive therapies are applied and no clear
Hermann Einsele is a Full Professor of Internal Medicine and Director of Medical Clinic
advantage can yet be demonstrated for one of the therapies.
II at the Julius Maximilians University in Würzburg. He is an active member of various
Ongoing and new prospective studies will help to clarify the role of
scientific organisations and Chairman of the German Study Group on Multiple
Myeloma. In 2003, he received the van Bekkum-Award from the European Society of
prophylactic, pre-emptive and CMV-directed immunotherapy not
Blood and Marrow Transplantation. His research interests include multiple myeloma,
only to control CMV infection but also to prevent indirect CMV-
stem cell transplantation and T-cell therapy.
related complications. ■
1. Staras SA, Dollard SC, Radford KW, et al., Seroprevalence 17. Mañez R, Breining MC, Linden P, et al., Post-transplant cytomegalovirus in adult renal transplant recipients, Am J
of cytomegalovirus infection in the United States, lymphoproliferative disease in primary Epstein-Barr virus Transplant, 2006;6:2134–43.
1988–1994, Clin Infect Dis, 2006;43:1143–51. infection after liver transplantation: the role of 30. Kalil AC, Levitsky J, Lyden E, et al., Preemptive therapy and
2. Koch S, Solana R, DelaRosa O, Pawelec G, Human cytomegalovirus disease, J Infect Dis, 1997;176:1462–7. universal prophylaxis for cytomegalovirus in solid organ
cytomegalovirus infection and T-cell immunosenescence: 18. Boeckh M, Nichols WG,The impact of cytomegalovirus transplant recipients: a meta-analyses, 4th Annual
a mini review, Mech Ageing Dev, 2006;127:538–43. serostatus of donor and recipient before hematopoietic Meeting of IDSA, 2004;167: abstract 639.
3. Pawelec G, Akbar A, Caruso C, et al., Human stem cell transplantation in the era of antiviral prophylaxis 31. Snydman DR, Counterpoint: prevention of
immunosenescence: is it infectious?, Immunol Rev, and preemptive therapy, Blood, 2004;103:2003–8. cytomegalovirus infection and CMV disease in recipients
2005;205:257–68. 19. Lowance D, Neumayer HH, Legendre CM, et al., of solid organ transplants: the case for prophylaxis, Clin
4. DelaRosa O, Pawelec G, Peralbo E, et al., Immunological Valacyclovir for the prevention of cytomegalovirus disease Infect Dis, 2005;40:709–12.
biomarkers of ageing in man: changes in both innate and after renal transplantation. International Valacyclovir 32. Einsele H, Hebart H, Kauffmann-Schneider C, et al., Risk
adaptive immunity are associated with health and Cytomegalovirus Prophylaxis Transplantation Study Group, factors for treatment failures in patients receiving PCR-
longevity, Biogerontology, 2006;7:471–81. N Engl J Med, 1999;340:1462–70. based preemptive therapy for CMV infection, Bone Marrow
5. Solana R, Pawelec G, Tarazona R, Aging and innate 20. Loebe M, Schuler S, Zais O, et al., Role of cytomegalovirus Transplant, 2000;25:757–63.
immunity, Immunity, 2006;24:491–4. infection in the development of coronary artery disease in 33. Krause H, Hebart H, Jahn G, et al., Screening for CMV-
6. Franco A, Jiménez L, Aranda I, et al., Diffuse the transplanted heart, J Heart Transplant,1990;9:707–11. specific T-cell proliferation to identify patients at risk of
lymphoproliferative disease after renal transplantation 21. Koskinen PK, Krogerus LA, Nieminen MS, et al., developing late onset CMV disease, Bone Marrow Transplant,
and its relation with Epstein-Barr virus. Experience at one Cytomegalovirus infection-associated generalized 1997;19:1111–16.
center, Nefrología, 2002;22:463–9. immune activation in heart allograft recipients: a study of 34. Briceño J, Torre-Cisneros J, Sánchez-Guijo P, Pera-Madrazo
7. Hodson E, Jones C, Webster A, et al., Antiviral medications cellular events in peripheral blood and endomyocardial C, Cyclosporine and anti-cd3 blockade of lymphocyte
to prevent cytomegalovirus disease and early death in biopsy specimens, Transpl Int, 1994;7:163–71. apoptosis induced by cytomegalovirus antigens, Transplant
recipients of solid-organ transplants: A systematic review 22. Valantine HA, Gao SZ, Menon SG, et al., Impact of Proc, 1999;31:1370.
of randomised controlled trials, Lancet, 2005;365:2105–15. prophylactic immediate posttransplant ganciclovir on 35. Strippoli GFM, Hodson EM, Jones C, Craig JC, Pre-emptive
8. Rowshani A, Bemelman F, Leeuwen E, et al., Clinical and development of transplant atherosclerosis: a post hoc treatment for cytomegalovirus viremia to prevent
immunologic aspects of cytomegalovirus infection in solid analysis of a randomized, placebo-controlled study, cytomegalovirus disease in solid organ transplant
organ transplant recipients, Transplantation, 2005;79:381–6. Circulation, 1999;100:61–6. recipients, Transplantation, 2006;81:139–45.
9. Rubin R, Prevention of cytomegalovirus infection in organ 23. Wagner JA, Ross H, Hunt S, et al., Prophylactic ganciclovir 36. Lacey SF, Gallez-Hawkins G, Crooks M, et al.,
transplant recipients, Transpl Infect Dis, 2000;2:99–100. treatment reduces fungal as well as cytomegalovirus Characterization of cytotoxic function of CMV-pp65-
10. Ljungman P, ß-Herpesvirus challenges in the transplant infections after heart transplantation, Transplantation, specific CD8+ T-lymphocytes identified by HLA tetramers
recipient, J Infect Dis, 2002;186(Suppl. 1):S99–109. 1995;60:1473–7. in recipients and donors of stem-cell transplants,
11. George MJ, Snydman DR, Werner BG, et al., The Boston 24. Einsele H, Ehninger G, Schneider EM, et al., High Transplantation, 2002;74:722–32.
Center for Liver Transplantation CMVIG-Study Group. The frequency of graft-versus-host-like syndromes following 37. Einsele H, Roosnek E, Rufer N, et al., Infusion of
independent role of CMV as a risk factor for invasive syngeneic bone marrow transplantation, Transplantation, cytomegalovirus (CMV)-specific T-cells for the treatment of
fungal disease in orthotopic liver transplant recipients, 1988;45:579–85. CMV infection not responding to antiviral chemotherapy,
Am J Med, 1997;103:106–13. 25. Soderberg C, Sumitran-Karuppan S, Ljungman P, Moller E, Blood, 2002;99:3916–22.
12. Singh N, Cytomegalovirus infection in solid organ CD13-specific autoimmunity in cytomegalovirus-infected 38. Riddell SR, Watanabe KS, Goodrich JM, et al., Restoration
transplant recipients: new challenges and their immunocompromised patients, Transplantation, 1996;61: of viral immunity in immunodeficient humans by adoptive
implications for preventive strategies, J Clin Virol, 594–600. transfer of T-cell clones, Science, 1992;257:238–41.
2006;35:474–7. 26. Larssen K, Aschan J, Remberger M, et al., Reduced risk for 39. Grigoleit GU, Kapp M, Hebart H, et al., Dendritic cell
13. El-Sabrout R, Radovancevic B, Ankoma-Sey V, Buren C, extensive chronic graft-versus-host disease in patients vaccination in allogeneic stem cell recipients: induction of
Guillain-Barré syndrome after solid organ transplantation, receiving transplants with human leukocyte antigen- human cytomegalovirus (HCMV)-specific cytotoxic
Transplantation, 2001;71:1311–16. identical sibling donors given polymerase chain reaction- T-lymphocyte responses even in patients receiving a
14. Smith R, CMV prophylaxis: a useful step towards based preemptive therapy against cytomegalovirus, transplant from an HCMV-sero-negative donor, J Infect Dis,
prevention of post-transplant diabetes?, Diabetologia, Transplantation, 2004;77:526–31. 2007;196:699–704.
2004;47:1473–5. 27. Nichols WG, Boeckh M, Recent advances in the therapy 40. Winston DJ, Young JA, Pullarkat V, Maribavir prophylaxis for
15. Addo MM, Rosenberg ES, Cellular immune responses in and prevention of CMV infections, J Clin Virol, 2000;16: prevention of cytomegalovirus infection in allogeneic
transplantation-associated chronic viral infections, Transpl 25–40. stem cell transplant recipients: a multicenter, randomized,
Infect Dis, 2002;4:31–40. 28. Paya C, Prevention of cytomegalovirus disease in double-blind, placebo-controlled, dose-ranging study,
16. Grigoleit U, Riegler S, Einsele H, et al., Human recipients of solid-organ transplants, Clin Infect Dis, Blood, 2008;111:5403–10.
cytomegalovirus induces a direct inhibitory effect on 2001;32:596–603. 41. Fishman JA, Emery V, Freeman R, et al., Cytomegalovirus
antigen presentation by monocyte-derived immature 29. Khoury JA, Storch GA, Bohl DL, et al., Prophylactic versus in transplantation. Challenging the status quo, Clin
dendritic cells, Br J Haematol, 2002;119:189–98. pre-emptive oral valganciclovir for the management of Transplant, 2007;21:149–58.
44 EUROPEAN HAEMATOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68